Pharma major Dr Reddy’s Laboratories has launched Memantine hydrochloride tablets in the US market following an approval from the United States Food & Drug Administration (USFDA).
The tablet is a therapeutic equivalent generic version of Namenda (memantine HCl) tablets, a registered trademark of Merz Pharma GmbH & Co. KGaA. The brand had U.S. sales of approximately $1.4 billion for the most recent twelve months ending in May 2015 according to IMS Health. It is generally indicated in the treatment of Alzheimer’s disease.
Dr Reddy’s Memantine hydrochloride tablets 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets 10 mg are available in bottle count sizes of 60 and 500, the company said in a release issued here on Monday.
The company’s scrip gained 0.44 per cent on the Bombay Stock Exchange on Monday to end at Rs 3,758.75.